Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Alternatively, an inhibitor might suffer a loss-of-function mutation, lose its ability to regulate signalling and lose its functions as a tumour suppressor. Both types of change in Wnt signalling ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Allarity Therapeutics has announced a Phase 2 clinical trial to evaluate the combination of stenoparib, a dual PARP/Wnt pathway inhibitor, with temozolomide for patients with recurrent Small Cell ...

Allarity Therapeutics has announced that it will begin patient enrollment for a new clinical trial protocol of stenoparib, a dual PARP/Wnt pathway inhibitor, aimed at treating advanced ovarian cancer.

A recent study has uncovered the pivotal role of the transcription factor SOX9 in the development of hypospadias, a common ...

With these issues behind us, we can now fully focus on our mission of advancing our novel PARP/Wnt inhibitor through the clinical development plans we have already announced.” As previously ...

The protocol aims to deepen our understanding of stenoparib’s clinical benefit in a well-defined ovarian cancer patient population while also assessing its potential impact on the Wnt pathway ...

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...